Clinical trials: PET-CT
Kidney Neoplasms, Carcinoma, Renal Cell
Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
To learn whether Flourine-18 Fluoro-deoxi-glucose positron emission tomography / computed tomography (F-18 FDG PET/CT) and dynamic contrast enhanced magnetic resonance imaging (DCE MRI) are better predictors of response to…
- Conditions
- Kidney Neoplasms, Carcinoma, Renal Cell, Kidney (Renal Cell) Cancer
- Trial name
- NCT00537056
- Testing
- FDG PET CT, DCE MRI, F-18 Fluoro-deoxi-glucose
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Stanford University
Brain Metastases From Breast Cancer
F18 EF5 PET/CT Imaging in Patients With Brain Metastases From Breast Cancer
To estimate the presence of hypoxia in individual lesions after radiotherapy in patients with brain metastases from breast cancer as identified by F18 EF5 PET/CT imaging.
- Trial name
- NCT01985971
- Testing
- PET/CT Imaging
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer
This phase II trial studies how well 3'-deoxy-3'-18F fluorothymidine (18F-FLT) positron emission tomography (PET)/computed tomography (CT) works in predicting response in patients receiving chemotherapy and undergoing surgery for…
- Conditions
- Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Trial name
- NCT00572728
- Testing
- CT, 18F-FLT, PET
- Where
- 27 sites in United States
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)
Menopause, Obesity
Brown Adipose Tissue Activity in Pre- and Postmenopausal Women
The physiological relevance of brown adipose tissue (BAT) in humans is largely unknown. The investigators have shown that suppressing ovarian function in premenopausal women reduces resting energy expenditure (REE), and this is…
- Trial name
- NCT02927392
- Testing
- Leuprolide acetate
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Recurrent Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma
A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC
This study is being done to compare a special type of Positron Emission Tomography (PET) scan with CT scan in patients with surgically removable lung cancer to see which method is more useful in measuring a response to treatment.
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma
- Trial name
- NCT00963807
- Testing
- Cisplatin, CT, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver Cancer
This phase II trial studies how well 68Ga-PSMA PET/MRI or PET/CT works in early detection of liver cancer. 68Gallium-PSMA is a radioactive tracer designed to circulate through the body and attach itself to the prostate- specific…
- Trial name
- NCT04762888
- Testing
- Computed Tomography, Gallium Ga 68 Gozetotide, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Mayo Clinic
Cancer of the Prostate
Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer
The main aim is to assess the impact of using 18F-fluciclovine (as a PET imaging radiotracer) on the clinical and treatment decision required for managing patients with biochemically recurrent prostate cancer (BCR) who are being…
- Trial name
- FALCON (NCT02578940)
- Testing
- 18F-Fluciclovine PET CT
- Where
- 7 sites in United Kingdom
- Volunteers
- 104 people
- Sponsor
- Blue Earth Diagnostics
Prostate Cancer
A Phase II Study to Evaluate Axumin PET/CT for Risk Stratification for Prostate Cancer
To investigate the utility of fluciclovine F 18 for evaluation for metastatic disease in men undergoing laser focal therapy of prostate cancer and the impact on inclusion for a focal therapy cohort.
- Trial name
- NCT03373006
- Testing
- Axumin PET/CT
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- HALO Diagnostics
Brain Cancer
A Comparison of MRI Perfusion and FDG PET/CT to Distinguish Between Radiation Injury and Tumor Progression
This study will examine if MRI perfusion and PET/CT can tell growing tumor and radiation injury apart. MRI perfusion looks at the blood vessels in the tumor. PET/CT looks if the tumor cells are actively growing.
- Trial name
- NCT01604512
- Testing
- MRI perfusion and PET/CT scans
- Where
- 6 sites in United States
- Volunteers
- 148 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Castration-resistant Prostate Cancer
Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
This is a master protocol designed to evaluate the safety and efficacy of investigational therapies in participants with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT04631601
- Testing
- Acapatamab, Enzalutamide, Abiraterone
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 55 people
- Sponsor
- Amgen
Prostate Adenocarcinoma
68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer
Prostate cancer (PC) remains the most-common non-cutaneous cancer diagnosed in American males, accounting for an estimated 174,560 estimated new cases and 31,620 estimated deaths in 2019.
- Trial name
- NCT02624518
- Testing
- 68Ga-RM2, Magnetic Resonance Imaging, Positron Emission Tomography
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- Andrei Iagaru
Prostate Cancer, Prostate Cancer Metastatic
MSG Use With 18F-DCFPyL PET/CT Imaging
18F-DCFPyL is an agent that binds to prostate specific membrane antigen (PSMA). Due to high levels of PSMA in prostate cancer, treatments targeting PSMA have been developed to deliver therapy to these specific target cells.
- Conditions
- Prostate Cancer, Prostate Cancer Metastatic, Prostatic Neoplasm
- Trial name
- NCT03693742
- Testing
- 18F-DCFPyL PET/CT scan, MSG drink
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- British Columbia Cancer Agency
Prostatic Neoplasms, Prostate Cancer
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
The purpose of this study was to evaluate the diagnostic performance of [18F]CTT1057 as a PET imaging agent for detection and localization of PSMA positive tumors using histopathology as Standard of Truth (SoT).
- Trial name
- GuideView (NCT04838626)
- Testing
- [18F]CTT1057
- Where
- 16 sites in United States, France and 3 more
- Volunteers
- 195 people
- Sponsor
- Novartis Pharmaceuticals
Recurrent Colon Cancer, Recurrent Rectal Cancer
2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer
This pilot phase II studies how well computed tomography (CT) and positron emission tomography (PET) imaging works in detecting disease in patients undergoing surgery for metastatic colorectal cancer.
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV A Bladder Cancer, Stage IV A Rectal Cancer
- Trial name
- NCT01821105
- Testing
- PET Scan, CT Scan, fludeoxyglucose F 18
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Prostate Neoplasm
F-18 Sodium Fluoride in Prostate Cancer
Background: Sodium fluoride (NaF) is a common compound that is found in various foods and can be used to increase bone strength.
- Trial name
- NCT01240551
- Testing
- F-18 NaF
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Feasibility of Using SPECT/CT Imaging to Map Lymphatic Drainage Patterns in Prostate Cancer Patients
The purpose of this study is to develop a practice procedure for lymphatic drainage mapping with the intent of providing a new tool that could potentially be used for radiation treatment planning.
- Trial name
- NCT01008969
- Testing
- SPECT-CT imaging
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
Intravenous Infiltration
Patterns and Prevalence of FDG Extravasation in PET/CT Scans
PET (Positron Emission Tomography) images are used to help make patient management decisions in staging and treatment assessment, often after a cancer diagnosis.
- Trial name
- Lucerno device (NCT03041090)
- Testing
- Lucerno ID (identification) System
- Where
- United States
- Volunteers
- 133 people
- Sponsor
- St. Louis University
Prostate Cancer
PSMA Imaging of Localized Prostate Cancer
The present study is a phase II, open label, single-center, non-randomized, single-dose study. Twenty subjects in total will be enrolled at Weill Cornell Medical College (WCMC)/ NYPH.
- Trial name
- NCT03675451
- Testing
- 89ZR-DF-IAB2M, 68Ga-PSMA-HBED-CC
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Weill Medical College of Cornell University
Acute Myeloid Leukemia
FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia
This phase II trial studies fluorothymidine F 18 (FLT) positron emission tomography (PET)/computed tomography (CT) in measuring response in patients with previously untreated acute myeloid leukemia.
- Trial name
- NCT02392429
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 11 sites in United States
- Volunteers
- 87 people
- Sponsor
- National Cancer Institute (NCI)
Muscle Invasive Bladder Cancer
Role of FDG-PET CT in the Management of Muscle Invasive Bladder Cancer
Bladder cancer is the seventh cause of cancer mortality in France. Overall survival is poor, between 45 and 50% at 5 years. Optimal staging of lymph nodes and metastasis is crucial for treatment decision of muscle invasive…
- Trial name
- TEP-Vessie (NCT04053101)
- Testing
- PET CT
- Where
- 2 sites in France
- Volunteers
- 130 people
- Sponsor
- Institut Bergonié